STATEMENT OF PROFIT AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2020 Consolidated Entity Note 2020 2019 $ $ Total revenues 2(a) 32,565,423 31,047,776 Interest income 2(b) 562,928 564,657 Other income 2(c) 781,319 886,037 Total expenses 2(d) (20,773,199) (14,383,643) Profit before income tax benefit 13,136,471 18,114,827 Income tax benefit 3(a) 3,510,388 19,333 Profit […]
Annual Report
GROWTH AND EXPANSION CLINUVEL is well positioned to build on its established commercial and research and development operations. The Company is expanding access to its drug SCENESSE® (afamelanotide 16mg) for patients with erythropoietic protoporphyria in Europe and the USA, as well as new jurisdictions, subject to regulatory approval and agreement on reimbursement. Drawing on expertise […]
FIFTEEN YEAR PERFORMANCE OVERVIEW CLINUVEL completed its fourth full year of commercial operations in the financial year ending 30 June 2020, recording a fourth consecutive annual profit and declaring a third consecutive annual dividend. A STORY OF STRATEGIC FOCUS Over the last fifteen years, CLINUVEL has implemented a deliberate and focussed strategy to develop and […]
CHAIR’S LETTER Dear Shareholders, Which expert in business could have predicted the year 2020? The question is, were we caught by surprise and could we have managed ourselves better? The year 2020, my first complete year as Chairman of CLINUVEL, has been overshadowed by the impact of COVID-19, and has therefore seen my main tasks […]
CLINUVEL IN THE MEDIA
MANAGING DIRECTOR’S LETTER Dear Shareholders, INTRODUCTION I contemplate CLINUVEL’s successful progress and financial results in 2020 in contrast with the unforeseen pandemic and various containment measures unfolding around the world. It has been a surrealistic series of events in the past year, the emergence of a new epoch and existence for all of us. In […]
CLINUVEL IN THE NEW WORLD ORDER INTRODUCTION The coronavirus pandemic has changed the world in which we live and operate. How we engage with one another, manage work and life, produce goods and services, and manage the impact of the increase in public spending incurred to support people and economic activity has changed to varying […]
INNOVATION IN DNA REPAIR CLINUVEL’S FOCUS ON DNA REGENERATION The backbone of human life is created by two structures forming our genetic material: pyrimidines and purines, which in turn consist of four nucleotides adenine (A), thymine (T), guanine (G), and cytosine (C). These form the DNA-helix which carries our present and future make-up, our genetic codes. Human physiology […]
SCENESSE® (afamelanotide 16mg) REPAIRS DNA DAMAGE CAUSED BY UV AND LOWERS RISKS OF SKIN CANCERS Click below to expand the image